Month: March 2022

  VANCOUVER, British Columbia, March 30, 2022 (GLOBE NEWSWIRE) — K92 Mining Inc. (“K92” or the “Company”) (TSX: KNT; OTCQX: KNTNF) is pleased to announce results from its financial statements for the three and twelve months ended December 31, 2021. SafetyStrong focus on safety with zero lost time incidents (“LTI”) in the fourth quarter. Since the start of operations, Kainantu has had one of the best safety records in the Australasia region.Proactive and focused management of COVID-19. K92 has continuously operated throughout the COVID-19 pandemic, has strong preventative and response plans, with pandemic resiliency strengthening through ongoing vaccination programs.ProductionFourth Quarter 2021Record quarterly tonnage of 99,713 tonnes treated, a 45% increase from Q4 2020.Record quarterly gold equivalent (“AuEq”) production...

Completes Year of Strong Organic Growth and Builds on New B2B Strategy Q4 Revenue and Adjusted EBITDA up 28% YoY to $54.1 Million and 6% to $4.8 Million, Respectively FY 2021 Revenue and Adjusted EBITDA up 28% YoY to $202.7 Million and 33% to $22.5 Million, Respectively PHOENIX, March 30, 2022 (GLOBE NEWSWIRE) —  TILT Holdings Inc. (“TILT or the “Company”) (NEO: TILT) (OTCQX: TLLTF), a global provider of cannabis business solutions that include inhalation technologies, cultivation, manufacturing, processing, brand development and retail, is reporting its financial and operating results for the three and twelve months ended December 31, 2021. All financial information is provided in U.S. dollars unless otherwise indicated. “2021 was a strong year for TILT—growing organically, building our team, and implementing the new B2B strategy...

Conference Call Today at 4:30 p.m. ET SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) — Beam Global, (Nasdaq: BEEM, BEEMW), (the “Company”), the leading provider of innovative sustainable products and technologies for electric vehicle (EV) charging, energy storage, energy security and outdoor media, today announced the financial results for the fiscal year ended December 31, 2021. Fiscal 2021 and Recent Company HighlightsGenerated record annual revenues of $9.0 million in 2021 134% growth in new orders year-over-year 67% growth in system deliveries year-over-year 66% growth in Q4 2021 system deliveries over Q3 2021 Acquired energy storage leader AllCell Technologies in an all-stock transaction Record revenue of $1.9M and orders of $2.9M in the first full year on the federal GSA contract Received the largest single order in company...

BENSALEM, Pa., March 30, 2022 (GLOBE NEWSWIRE) — StoneMor Inc. (NYSE: STON) (“StoneMor” or the “Company”), a leading owner and operator of cemeteries and funeral homes, today reported operating and financial results for the fourth quarter and year ended December 31, 2021.  Investors are encouraged to read the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2021 when it is filed with the Securities and Exchange Commission (the “SEC”), which will contain additional details, and will be posted at www.stonemor.com. FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL PERFORMANCERevenues for the fourth quarter were $79.3 million compared to $74.9 million in in the fourth quarter in the prior year.  Full year revenues were $322.8 million compared to $279.5 million in the prior year period. Cemetery segment operating...

– Pipeline Includes Three New Chemical Entities with Clinical Proof-Of-Concept (POC) Following CRN04894 and CRN04777 Phase 1 Readouts in 2021 – – Advancing Phase 3 PATHFNDR Program Evaluating Paltusotine in Acromegaly – – Advancing a Preclinical Parathyroid Hormone Receptor Antagonist Program Using the Drug Development Paradigm Followed by Paltusotine, CRN04894, and CRN04777 – – Co-founded Radionetics Oncology with 5AM Ventures and Frazier Healthcare Partners – – Management Hosting Webcast and Conference Call Today at 4:30 p.m. Eastern Time to Discuss New Multiple-Ascending Dose Study Data that Further Support Clinical POC for CRN04777 – SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization...

IZEA Q4 2021 Bookings Conversion Chart Managed Services Bookings to Revenue ConversionORLANDO, Fla., March 30, 2022 (GLOBE NEWSWIRE) — IZEA Worldwide, Inc. (NASDAQ: IZEA), the premier provider of influencer marketing technology, data, and services for the world’s leading brands, reported its financial and operational results for the fourth quarter ended December 31, 2021. Q4 2021 Financial Summary Compared to Q4 2020Total revenue increased 62% to an all-time record of $10.3 million compared to $6.4 million. Managed Services revenue increased 69% to $9.9 million, compared to $5.8 million. SaaS Services revenue decreased 17% to $0.4 million, compared to $0.5 million. Total costs and expenses increased 37% to $10.3 million, compared to $7.5 million. Net income was $0.3 million compared to a net loss of $1.1 million. Adjusted...

MIAMI, March 30, 2022 (GLOBE NEWSWIRE) — Motorsport Games Inc. (NASDAQ: MSGM) (“Motorsport Games” or the “Company”) today reported financial results for its fourth quarter and fiscal year ended December 31, 2021. The Company has also posted a 2021 Year End Review video and Q4 ‘21 and fiscal year-end earnings slides highlighting key milestones that occurred in the period, which are accessible on the Company’s investor relations website. Dmitry Kozko, Chief Executive Officer of Motorsport Games, commented, “We head into 2022 with an incredible arsenal of world-class IP, following a transformational year for our Company in which we went public, expanded organically and through acquisitions and we launched new major NASCAR-branded gaming experiences. January 2022 brought our full-release of KartKraft racing for PCs, as well as a significant...

EDEN PRAIRIE, Minn., March 30, 2022 (GLOBE NEWSWIRE) — Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, today reported fourth quarter and full year 2021 financial results and provided a corporate update. “The need for organ transplants is greater than ever and Miromatrix is proud to be one of a small group of companies at the forefront of developing alternatives to human donor organ transplants,” said Jeff Ross, Ph.D., Miromatrix CEO. “We continue to believe our bioengineered organ technology platform is the most differentiated technology in the category, which I will expand upon during our conference call. We accomplished several key milestones in 2021 and are very excited about...